Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + trastuzumab + chemotherapy in HER2-positive metastatic breast cancer with or without brain metastases
ChiCTR2100054759Phase 2Recruiting
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib and trastuzumab in breast cancer, sponsored by Chinese Academy of Medical Sciences. Primary endpoint: overall response rate. Started May 2019; status: recruiting.
02
Drugs
pyrotinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100054759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054759.